ERJ+editorial+final+V3.pdf (166.87 kB)
Download file

Delivering high value therapies in COPD: the secret is in the marketing

Download (166.87 kB)
journal contribution
posted on 11.06.2019, 08:43 by Helen Ashdown, Michael Steiner
There are a wide range of therapies now available for people suffering with chronic obstructive pulmonary disease (COPD), both pharmacological and non-pharmacological [1]. However, there has been recent recognition that non-pharmacological approaches (for example smoking cessation and pulmonary rehabilitation) deliver the highest value in terms of patient benefit in relation to cost [2]. It is also evident that the provision of high value therapies in clinical practice is frequently sub-optimal, as illustrated in figure 1 summarising data from a recent, comprehensive primary care audit of COPD care in Wales [3]. In healthcare systems such as Australia and the UK, where 90% of healthcare is delivered in primary care [4], there is now a need to investigate how best to implement such high value interventions in primary care.

History

Citation

European Respiratory Journal, 2019, 53: 1900215

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

AM (Accepted Manuscript)

Published in

European Respiratory Journal

Publisher

European Respiratory Society

issn

0903-1936

Acceptance date

01/04/2019

Copyright date

2019

Publisher version

https://erj.ersjournals.com/content/53/4/1900215

Notes

The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

Categories

Keywords

Exports